E-134 In-hospital complications of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients. (22nd July 2019)

• Record Type: Journal Article
• Authors: Tong, K; Wang-Selfridge, A; Colburn, T; Brauer, P
• Is Part Of: Journal of neurointerventional surgery. Volume 11(2019)Supplement 1
• Page Start: A122
• Page End: A122
• Publication Date: 2019-07-22
• Subjects: Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2019-SNIS.209
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Background: Intravenous thrombolysis remains an underutilized treatment for acute ischemic stroke (AIS) due to several relative and absolute contraindications. Previous studies have investigated outcomes for the majority of AIS patients receiving thrombolysis without including the subset of renal failure patients requiring dialysis. This study aims to investigate short-term outcomes of thrombolytic treatment for dialysis-dependent patients who suffered in-hospital complications. Methods: This retrospective cohort study utilized data from the 2012–2015Q3 Nationwide Inpatient Sample (NIS). ICD-9 codes identified adult patients (ages 18+) who received thrombolytic treatment for AIS while on dialysis for renal failure, and then further isolated patients diagnosed with in-hospital complications. Complications include intracerebral hemorrhage (ICH), pneumonia, urinary tract infection (UTI), sepsis, deep venous thrombosis (DVT), and pulmonary embolism (PE). Data for patients who were missing important clinical identifiers (age, gender, race, mortality) and did not receive IV thrombolysis or dialysis were excluded. Data analyses assessed hospital mortality rate, length of stay (LOS), inpatient charges, and average age of admission. Results: Of the 5, 745 encounters with AIS patients treated with thrombolysis while on dialysis for renal failure, 189 dialysis-dependent patients had in-hospital complications. These patients experienced: Lower rate of ICH (1.1% DD vs. 4.6% no DD, p<0.0001). Higher rate of pneumonia (5.4% DD vs. 2.9% no DD, p<0.0001). Lower rate of UTI (2.5% DD vs. 4.2% no DD, p<0.0001). Higher rate of sepsis (11.4% DD vs. 1.9% no DD, p<0.0001). Higher rate of DVT (15.6% DD vs. 3.2% no DD, p = 0.004). No significant difference in rate of PE (3.3% DD vs. 3.3% no DD). Conclusion: This study aims to inform physicians to better manage dialysis-dependent renal failure patients receiving IV thrombolysis for AIS. These patients experience lower rates of ICH and UTI, and higher rates of pneumonia, sepsis, and DVT. These findings suggest that placing clinical focus on pneumonia, sepsis, and/or DVT prevention before administering IV thrombolysis may be critical for improving short-term in-hospital outcomes for AIS. Future research should aim to investigate different thrombolytic agents to determine the optimal choice for dialysis-dependent patients with pneumonia, sepsis, and DVT, as well as delineate differences in approaches to achieve best outcomes for dialysis-dependent renal failure patients receiving IV thrombolysis. Disclosures: K. Tong: None. A. Wang-Selfridge: None. T. Colburn: None. P. Brauer: None.